Abstract
Brachytherapy—radiation delivered close to or within a tumor—had its origins at the beginning of this century. Its use in prostate cancer was delayed first by the view that this was a relatively radioresistant cancer and then by clinical experience showing high failure and morbidity rates. More recently, technological innovations such as ultrasonography and computer-based treatment planning have made prostate brachytherapy a reasonable treatment option for many patients.
Get full access to this article
View all access options for this article.